Ligand Bolsters Business Development Team with Key Hires to Drive Royalty Financing Growth
Summary
Ligand Pharmaceuticals announced the appointment of Peter Renehan and Lee Brown as Vice Presidents of Investments and Business Development, alongside an expanded role for Lauren Hay as VP of Portfolio Strategy and Investments. These strategic hires, bringing experience from firms like Blackstone Life Sciences and Third Bridge Group, are intended to significantly strengthen Ligand's core capability in sourcing and transacting royalty financing opportunities. This move signals a proactive commitment to strategic growth and optimizing its extensive portfolio of biopharmaceutical royalties, which is crucial for a company operating as a royalty aggregator. Investors will be watching for future announcements of new royalty acquisitions or portfolio enhancements driven by this expanded team.
At the time of this announcement, LGND was trading at $204.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $93.58 to $227.92. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.